It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Uncertainty Quantification in Cost-effectiveness Analysis for Stochastic-based Infectious Disease Models: Insights from Surveillance on Lymphatic Filariasis

Mary Chriselda Antony Oliver^{a,h,∗}, Matthew Graham^h, Ioanna Manolopoulou^{b,c}, Graham F. Medley^d, Lorenzo Pellis^e, Koen B Pouwels^f, Matthew Thorpe^g, T. Deirdre Hollingsworth^h

^aUniversity of Cambridge, Department of Applied Mathematics and Theoretical Physics, Wilberforce Road, Cambridge, CB3 0BN, UK ^bUniversity College London, Department of Statistical Science, Gower Street, London, WC1E 6BT, UK

^cThe Alan Turing Institute, London, NW1 2DB, UK

^dLondon School of Hygiene and Tropical Medicine, Centre for Mathematical Modelling of Infectious Disease and Department of Global Health and

Development, Keppel Street, London, WC1E 7HT, UK

^eUniversity of Manchester, Department of Mathematics, Oxford Road, Manchester, M13 9PL, UK

*^fUniversity of Oxford, Health Economics Research Centre, Nu*ffi*eld Department of Population Health, Oxford, OX3 7LF, UK*

^gUniversity of Warwick, Department of Statistics, Coventry, CV4 7AL, UK

^hUniversity of Oxford, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Oxford, OX3 7LF, UK

Abstract

Cost-effectiveness analyses (CEA) typically involve comparing effectiveness and costs of one or more interventions compared to standard of care, to determine which intervention should be optimally implemented to maximise population health within the constraints of the healthcare budget. Traditionally, cost-effectiveness evaluations are expressed using incremental cost-effectiveness ratios (ICERs), which are compared with a fixed willingness-to-pay (WTP) threshold. Due to the existing uncertainty in costs for interventions and the overall burden of disease, particularly with regard to diseases in populations that are difficult to study, it becomes important to consider uncertainty quantification whilst estimating ICERs.

To tackle the challenges of uncertainty quantification in CEA, we propose an alternative paradigm utilizing the Linear Wasserstein framework combined with Linear Discriminant Analysis (LDA) using a demonstrative example of lymphatic filariasis (LF). This approach uses geometric embeddings of the overall costs for treatment and surveillance, disability-adjusted lifeyears (DALYs) averted for morbidity by quantifying the burden of disease due to the years lived with disability, and probabilities of local elimination over a time-horizon of 20 years to evaluate the cost-effectiveness of lowering the stopping thresholds for post-surveillance determination of LF elimination as a public health problem. Our findings suggest that reducing the stopping threshold from <1% to <0.5% microfilaria (mf) prevalence for adults aged 20 years and above, under various treatment coverages and baseline prevalences, is cost-effective. When validated on 20% of test data, for 65% treatment coverage, a government expenditure of WTP ranging from \$500 to \$3,000 per 1% increase in local elimination probability justifies the switch to the lower threshold as cost-effective.

Stochastic model simulations often lead to parameter and structural uncertainty in CEA. Uncertainty may impact the decisions taken, and this study underscores the necessity of better uncertainty quantification techniques within CEA for making informed decisions.

Keywords: Lymphatic filariasis, mathematical modelling, stopping threshold, cost-effective analysis, optimal transport

1. Introduction

² *1.1. Health Economics Motivation*

³ Global health systems face enormous challenges as a result ¹⁶ of the rising demand for healthcare services and the finite re- $\frac{1}{17}$ sources available to them. While other factors such as equity $_{18}$ ϵ may play a role, a common aim for governments is to max- $\overline{7}$ imise overall population health within the constraints of the $\overline{20}$ available healthcare budget. Planning, managing, and assess- $_{21}$ ing health systems heavily relies on economic factors. The best $_{22}$ ¹⁰ use of limited resources is guided by health economic analy- $_{23}$ 11 ses, which provide cohesive techniques for evaluating the cost- $_{24}$ ¹² effectiveness of health interventions.

¹³ The economic evaluation of health interventions is normally ¹⁴ based on the outcome and cost of the interventions. Depending ¹⁵ on the choice of how the outcome and intervention is evaluated, one of the main methodologies used is the cost-effectiveness analysis (CEA). This is an economic evaluation technique in which two or more health interventions are compared in terms of incremental costs and incremental effects compared to standard of care, with the cost-effectiveness expressed using the incremental cost-effectiveness ratio (ICER) which is a measure dividing the incremental costs by the incremental effects. Most countries that regularly use CEA to guide policy decisions around the implementation and reimbursement of inter-²⁵ ventions specify in their health-economic guidelines that cost-²⁶ utility analyses should be used, where the denominator of the

[∗]Corresponding author: mca52@cam.ac.uk; postal address: DAMTP, Cen-Corresponding author: mca52@cam.ac.uk; postal address: DAMTP, Cen-₂₇ ICER is expressed in quality-adjusted life-years (QALYs) or
tre for Mathenine: This iPhene in Manority Jerusales and the propertional process of the li

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

disability-adjusted life-years (DALYs). The latter is more fre- $\frac{1}{85}$ ²⁹ quently used in low- and middle-income countries (LMICs).

30 Given the focus on LMICs in this paper, DALYs will be used 87

31 from here onwards. 32 The interpretation of the ICER depends on where it lies on 89 33 the cost-effectiveness plane (refer Figure 1 in [\[20\]](#page-11-0)). If the new 90 ³⁴ intervention is more effective and saves money compared to ³⁵ standard of care (South East quadrant), or the new intervention ³⁶ is less effective and more costly compared to standard of care 37 (North West quadrant), the ICER is negative and interpretation 92

38 is simple. In the former case the new intervention should clearly 93 39 be adopted from a cost-effectiveness point of view, whereas in 94 ⁴⁰ the latter case the intervention is clearly worse and should not ⁴¹ be adopted.

42 To determine whether an intervention likely improves over-97 43 all population health within the healthcare budget constraints, 98 44 the ICER can be compared with a cost-effectiveness threshold 99 ⁴⁵ in situations where the intervention is more costly and more ⁴⁶ effective (North East quadrant) or less costly and less effec-47 tive (South West quadrant). Assuming the decision-maker in-102 ⁴⁸ deed wants to maximise overall population health, symmetrical ⁴⁹ threshold should be applied for both quadrants, whereby inter-⁵⁰ ventions that are more effective and more costly should remain 51 below the threshold and interventions that are less effective and 106 ⁵² less costly should remain above the threshold.

53 If a new intervention costs more per DALY avoided than the 108 54 healthcare it displaces, health opportunity costs exceed health109 55 benefits, and implementing the new intervention would be ex-110 ⁵⁶ pected to lead to an overall reduction in population health mea-57 sured in DALYs. Theoretically, the cost-effectiveness threshold112 58 [\[12;](#page-11-1) [48;](#page-12-0) [35\]](#page-12-1) should reflect the point at which this occurs. Thus, 113 ⁵⁹ given the available budget, interventions that are more costly ⁶⁰ and more effective with an ICER below the threshold are ex-115 ⁶¹ pected to improve overall population health, while similar in-116 62 terventions with an ICER above the threshold are expected to 117 ⁶³ worsen overall population health.

64 Characterizing uncertainty is crucial in CEA, particularly119 ⁶⁵ when evaluating the need for additional evidence. Value of₁₂₀ Information (VoI) analysis enhances CEA by quantifying the 121 ⁶⁷ benefit of reducing uncertainty in decision-making. In health₁₂₂ decision-analytic models, VoI assesses the potential benefit ob- taining additional data aimed at reducing uncertainty in key parameters influencing decision uncertainty. Two key uncer- tainties are model input values and model structure, whereby₁₂₆ VoI analyses in the literature typically only focus on parameter 127 uncertainty and completely ignore model structure uncertainty. These models are typically law-driven due to a lack of long- term data. To quantify input uncertainty, a probability distribu- tion for true input values is propagated through the model using 131 Monte Carlo sampling, known as probabilistic sensitivity anal-132 ysis (PSA) [\[15;](#page-11-2) [43\]](#page-12-2). However, PSA only addresses input uncer- tainty, not structural uncertainty, which is harder to quantify and 134 80 requires judgments about the model's real-life representation. 135 81 Despite its potential, VoI analysis [\[56\]](#page-12-3) is constrained by₁₃₆ structural uncertainties, which are rarely quantified in model-137 83 based analyses. Not quantifying structural uncertainty implies 84 that the model is a perfect representation of real-world pro-139 cesses and relationships. While VoI analysis for structural uncertainty using model selection and model averaging has been explored previously $[44; 6]$ $[44; 6]$, methods in this area are still underdeveloped. Addressing these limitations is essential to fully leverage VoI analysis in making informed and effective healthcare policy decisions.

⁹¹ *1.2. Theoretical Background on Lymphatic Filariasis*

Lymphatic filariasis (LF), a debilitating neglected tropical disease caused by parasitic worms transmitted through mosquitoes, affects about 882 million people across 44 coun-tries [\[54\]](#page-12-5). In 2000, the World Health Organization (WHO) launched the Global Program to Eliminate Lymphatic Filariasis (GPELF), aiming to eradicate LF as a public health problem (EPHP) in 73 endemic nations by 2020 [\[53\]](#page-12-6). By 2021, 19 countries, including Bangladesh and Lao People's Democratic Republic, were validated as having achieved EPHP, with 11 others under surveillance after halting large-scale treatment [\[53;](#page-12-6) [54\]](#page-12-5).

The primary intervention involves annual mass drug administration (MDA) for at least five years in affected areas, employing drug combinations such as diethylcarbamazine (DEC) + albendazole (DA) or albendazole + ivermectin (IA) [\[54\]](#page-12-5). Some areas also utilize a triple combination ivermectin + DEC + al-¹⁰⁷ bendazole (IDA) [\[28;](#page-11-4) [24\]](#page-11-5). To assess MDA impact and determine if infection levels have dropped below stopping thresholds, WHO recommends epidemiological monitoring surveys and transmission assessment surveys (TAS). The TAS uses the samples of blood smears, typically surveying children aged 5 years and above for microfilariae (mf) prevalence [\[54\]](#page-12-5). Current MDA guidelines advise a minimum of 5 rounds of treatment before a pre-TAS is used to determine whether a first full TAS should be conducted, known as TAS-1. MDA can be stopped if TAS-1 is passed. Two subsequent surveys must also be passed before EPHP can be validated, TAS-2 and TAS-3, each within ¹¹⁸ 2–3 years of the previous assessment.

However, focusing solely on children may underestimate mf prevalence, potentially missing ongoing transmission due to higher mf prevalence in adults. This paper proposes to improve the sensitivity of TAS to evaluate mf prevalence in adults, targeting $\langle 0.5\% \rangle$ mf prevalence. This involves randomly sampling approximately 30 sites with 40-60 adults per site to replicate the characteristics of an evaluation unit (EU). Achieving and sustaining WHO goals necessitates effective surveillance, identifying new cases post-EPHP target attainment. Intensive surveillance thresholds ($\langle 2\%$ antigenamia (Ag), $\langle 1\%$ mf) may still be inadequate, especially in areas with *Culex* transmission vectors $[3; 16]$ $[3; 16]$. Mathematical and biological theories $[1]$ propose a transmission breakpoint influenced by local transmission conditions and biological factors, in helminth infections such as LF which depend on sexual reproduction of the parasites, where low worm burdens diminish onward transmission, potentially leading to disease extinction in deterministic scenarios. Studies, have suggested that the breakpoint might be substantially lower than 1% mf prevalence [\[19;](#page-11-9) [34\]](#page-12-7). Stochastic extinction can still occur above this breakpoint but with a lower probabil-ity [\[16\]](#page-11-7). If MDA are halted after reaching the breakpoint, the

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

¹⁴⁰ low-level remaining transmission will diminish gradually tak-¹⁴¹ ing a longer time for LF extinction.

 142 In this work, we aim to provide the first detailed model sim- 197 143 ulations of reducing the TAS stopping threshold in LF from 198 ¹⁴⁴ <1% to <0.5% mf prevalence in a sample of adults aged 20_{199}
¹⁴⁵ vears and above. This facilitates the understanding of the dif₂₀₀ years and above. This facilitates the understanding of the dif₂₀₀ ¹⁴⁶ ferent trade-offs between additional rounds of MDA treatment $_{147}$ and rebounds that apply to the design of surveillance strategies. ¹⁴⁸ In this context, modelling can help us to understand how ad-¹⁴⁹ justing the threshold used in TAS impacts decisions about the ¹⁵⁰ stop of interventions and at what cost. For many settings, a ¹⁵¹ reduction in the threshold increases the probability of elimina-¹⁵² tion, decreases the number of treatment rounds required, and ¹⁵³ reduces costs. Importantly, however, in certain circumstances ¹⁵⁴ (e.g., when coverage is lower), lower thresholds can imply an 155 increase in the number of rounds of treatment required to reach² ¹⁵⁶ that threshold (with increased costs) but help mitigate chronic 157 conditions (such as lymphoedema and hydrocele) and result in²¹¹ ¹⁵⁸ longer sustained elimination with fewer future rebounds.

159 To investigate the issues outlined above, here we use mathe-²¹² 160 matical models of the transmission dynamics of LF as a case²¹³ 161 study to assess the potential implications of modifying the²¹⁴ 162 threshold for TAS. The paper addresses a key question: What²¹⁵ 163 are the potential trade-offs encountered in uncertainty quantifi-²¹⁶ 164 cation of cost-effectiveness analysis on lowering the stopping²¹⁷ 165 threshold for TAS in adults aged 20 years and above from an²¹⁸ 166 economic, epidemiological and mathematical perspective? In²¹⁹ 167 this paper, we restrict to lowering the stopping threshold from²²⁰ ¹⁶⁸ <1% mf prevalence to <0.5% mf prevalence for a sample of ²²¹
¹⁶⁸ adults motivated by the work in [3] and [16] Importantly we adults motivated by the work in [\[3\]](#page-11-6) and [\[16\]](#page-11-7). Importantly, we ¹⁷⁰ focus on areas with *Culex* mosquitoes as the major transmission 171 vector using IA drug combinations for potential comparisons.

¹⁷² *1.3. Contributions*

173 This study investigates the following three specific sub-²²⁵ ¹⁷⁴ questions outlined below which highlight the key contributions²²⁶₂₂₇ ¹⁷⁵ of our work:

- 176 1. What is the interplay between the dynamics of infection on₂₂₉ 177 DALY burden and elimination? In Section [5](#page-7-0) we show the₂₃₀ ¹⁷⁸ monotonic behaviour of the DALY burden and probability
- 179 of elimination for different stopping thresholds, baseline₂₃₁ ¹⁸⁰ mf prevalences and MDA coverages.
- 181 2. What are the dynamics of the costs both pre and post-MDA₂₃₃ ¹⁸² surveillance when the stopping threshold is lowered? $In₂₃₄$ 183 Section [5](#page-7-0) we explain the tradeoff illustrated in the ob-₂₃₅ 184 served non-monotonic behaviour of the costs for different₂₃₆ 185 stopping thresholds, baseline prevalences and MDA cov-237 ¹⁸⁶ erages.
- ¹⁸⁷ 3. If lower stopping thresholds are required for elimination ¹⁸⁸ of transmission, then are we realistically able to measure ¹⁸⁹ them using current tools? In order to circumvent issues ¹⁹⁰ related to the ICERs to address this question using the ¹⁹¹ CEA framework in Section [2,](#page-2-0) we instead adopt a linear ¹⁹² formulation of Expected Incremental Net-Monetary Bene-¹⁹³ fit (EINMB) metric for fixed country-level WTP values as ¹⁹⁴ recommended by the several studies [\[38;](#page-12-8) [52\]](#page-12-9) for DALYs

averted and approximate the range of WTP for probabil-¹⁹⁶ ity of elimination (due to lack of data) in order to align with the goals of GPLEF. We also extend the analysis to quantify uncertainty with every additional sample size using Value of Information Analysis (VoI) with the help of Expected Value of Sample Size (EVSI) metric for the optimum WTP values per DALY averted and unit increase in the probability of elimination for different stopping thresholds and baseline prevalences. Finally, we propose an alternate paradigm, the Linear Wasserstein Framework in Section [3](#page-4-0) that might help us resolve some of the proposed limitations, particularly around structural uncertainty of the CEA framework.

Addressing these questions will help to assess whether lower thresholds have the potential to assist programmes in achiev-²¹⁰ ing LF local elimination goals and how such decisions impact programme costs aligning with the GPELF objectives.

²¹² *1.4. Outline of the paper*

We begin in Section [2](#page-2-0) by summarizing the theoretical framework for CEA. In addition, we prescribe an alternative paradigm that circumvents structural uncertainties of CEA us-ing the Linear Wasserstein framework in Section [3.](#page-4-0) The numer-ical implementation is then described in Section [4](#page-6-0) and tested in Section [5.](#page-7-0) Finally, we will discuss our findings and present our conclusions in Section [6.](#page-9-0) For the reader's convenience we have provided a list of key terminologies used in the manuscript in Table [C.15](#page--1-0) (see [Appendix C](#page--1-1) for more details).

2. Summary on Cost Effective Analysis (CEA) Framework

²²³ In this section, we extend the classic net-benefit framework to ²²⁴ include resource implications alongside aligning with GPLEF goals by incorporating elimination probabilities [\[2\]](#page-11-10). Additionally, we incorporate Value of Information (VoI) analysis which directly addresses the potential implications of current uncer-²²⁸ tainty, not only in terms of the likelihood of modifying the current decision in light of new and more definitive evidence, but also in terms of the opportunity cost of the incorrect decision.

²³¹ *2.1. Notation and Basic Concepts*

²³² Health economic decision making aims to determine the optimal intervention considering costs and health impacts of vari-²³⁴ ous clinical effectiveness. A key metric is the Incremental Cost-Effectiveness Ratio (ICER), defined as the ratio of the difference in costs (ΔC) to the difference in health impacts (ΔE) between two interventions:

$$
\text{ICER} = \frac{\Delta C}{\Delta E},\tag{1}
$$

Here, we use a cost-utility analysis, where health impacts (ΔE) are expressed in disability-adjusted life years ($\Delta DALYs$) averted by quantifying overall disease burden due to morbidity and mortality. In the current analyses, we only include effects on morbidity (e.g., lymphoedema, hydrocele) as we assumed the intervention has no impact on mortality. For our analysis,

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

we will use both DALYs averted and the probability of elim-276 ination. A strategy is considered cost-effective if the ICER does not exceed the health planner's WTP per DALY averted (WTP_{DALY}),

$$
\text{ICER} = \frac{\Delta C}{\Delta \text{DALYs}} \le \text{WTP}_{\text{DALY}}.\tag{2}
$$
²⁷

 248 The net-benefit framework circumvents issues with ICERs by²⁷⁹ 249 not having to deal with extended dominance (when one inter-²⁸⁰ 250 vention is less cost-effective than a combination of two or more²⁸¹ 251 interventions) by transforming the ICER into a linear additive²⁸² ²⁵² form, known as the net-monetary benefit (NMB).

$$
\Delta C \leq \text{WTP}_{\text{DALY}} \cdot \Delta \text{DALYs} =: 0 \leq \text{WTP}_{\text{DALY}} \cdot \Delta \text{DALYs} - \Delta C = \text{NMB}(\text{WTP}_{\text{DALY}}),
$$
 (3)²₂₀

²⁵³ By using NMB, which relies on single monetary values rather ²⁵⁴ than ratios, the framework simplifies the evaluation of mul-²⁵⁵ tiple interventions, regardless of which quadrant of the cost-²⁵⁶ effectiveness plane the ICER lies in. Given a Monte Carlo sam-257 ple of *N* iterates of the costs and DALYs averted (denoted by²⁸⁸ ²⁵⁸ the parameter set θ), a strategy is preferred over the comparator²⁸⁹
²⁵⁹ if the expected NMB exceeds zero: if the expected NMB exceeds zero:

$$
0 \leq \mathbb{E}_{\theta}(\text{NMB}(\theta_i, \text{WTP}_{\text{DALY}})),\tag{4}
$$

260 where θ is the parameter vector and $i = \{1, 2, \dots, N\}$ is the itera-
261 tions per parameter to denote the samples drawn from the joint tions per parameter to denote the samples drawn from the joint₂₉₂ ²⁶² distribution $p(\theta)$. Extending this framework to multistrategy₂₉₃ decision analysis between *J* strategies, the preferred strategy is decision analysis between *J* strategies, the preferred strategy is $_{294}$ the one that maximizes the $\mathbb{E}_{\theta}(\text{NMB}(\theta_i, \text{WTP}_{\text{DALY}}))$:

$$
\max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\theta}\Big(\text{NMB}\Big(j,\theta_i|\text{WTP}_{\text{DALY}}\Big)\Big).
$$
 (5)

²⁶⁵ We also include benefits related to the probability of elimina-²⁹⁹ tion of LF, aligning with GPELF goals using WTP per unit in- crease in probability of elimination (WTP $_{Elimination}$). The NMB is reformulated as:

$$
NMB(\theta_i) = 100 \cdot WTP_{Elimination} \times \Delta \mathbb{I}_{Elimination}(\theta_i)
$$

+
$$
WTP_{DALY} \times \Delta DALYs(\theta_i) - \Delta C(\theta_i),
$$
 (6)₃₀

269 Here, $\Delta \mathbb{I}_{\text{Elimination}}(\theta_i)$ is 1 if only one strategy achieves elimina-302 ion, and 0 otherwise such that $\Delta \mathbb{I}_{\text{Elimination}}(\theta_i) = \mathbb{I}_{\text{max}}^j$ (θi) −303 tion, and 0 otherwise such that $\Delta \mathbb{I}_{\text{Elimination}}(\theta_i) = \mathbb{I}_{\text{Elimination}}^j(\theta_i) - \mathbb{I}_{\text{Comparator}}^j(\theta_i)$ $\prod_{i=1}^{\text{Comparator}} (\theta_i)$. Analogous to the traditional NMB, the strategy that ought to be implemented is indicated by ²⁷² that ought to be implemented is indicated by,

$$
\max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\theta} \Big(\text{NMB}\Big(j,\theta_i|\text{WTP}_{\text{DALY}},\text{WTP}_{\text{Elimination}}\Big)\Big),\qquad(7)
$$

²⁷³ Simultaneously, the framework allows for a probabilis-²⁷⁴ tic interpretation of cost effectiveness by conditioning on 275 WTP_{DALY}, WTP_{Elimination} as follows,

$$
\mathbb{P}(j \text{ is CE}|{\text{WTP}_{\text{DALY}}}, {\text{WTP}_{\text{Elimination}}}) = \frac{1}{N} \sum_{i=1}^{N} \mathbb{M}(j, \theta_i), \quad (8)^{\text{30}}_{\text{31}}
$$

where

$$
\mathbb{M}(j, \theta_i) = \begin{cases} 1 & \text{arg max}_{j \in 1:J} \mathbf{NMB}\left(j, \theta_i | \mathbf{WTP}_{\text{DALY}}, \mathbf{WTP}_{\text{Elimination}}\right) \\ 0 & \text{Otherwise} \end{cases}
$$
(9)

The framework therefore presents a measure of uncertainty that the strategy with the highest expected NMB is optimal over all other strategies, given by the proportion of samples where the strategy has the highest NMB of all strategies.

In general terms, the Expected Value of Perfect Information $(EVPI)$ [\[8\]](#page-11-11) is the difference between the expected value of a decision made with perfect information and the expected value ²⁸⁴ of a decision made with current knowledge. It represents the ²⁸⁵ maximum amount a decision-maker would be willing to pay ²⁸⁶ for perfect information to avoid the potential losses associated ⁸⁸⁷ with uncertainty. EVPI is defined as,

$$
EVPI = \mathbb{E}_{\theta}(\max_{j=[1,2,\cdots,J]} NMB(j,\theta_i|WTP_{\text{DALY}}, WTP_{\text{Elimination}})) - \max_{j=[1,2,\cdots,J]} \mathbb{E}_{\theta}(NMB(j,\theta_i|WTP_{\text{DALY}}, WTP_{\text{Elimination}})).
$$
\n(10)

Here, the vector of parameters can be split in two components $\theta = (\phi, \psi)$, where ϕ is the subvector of parameters of 290 interest (i.e., those that could be investigated further) and ψ are
291 the remaining "nuisance" parameters: the remaining "nuisance" parameters:

$$
\max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\psi|\phi}(\text{NMB}(j,\theta_i | \text{WTP}_{\text{DALY}}, \text{WTP}_{\text{Elimination}})).
$$
 (11)

which is the value of learning ϕ with no uncertainty. Of course, we will never be in the position to completely eliminate the un-E₂₉₄ certainty on φ, so we then average over its current probability

equalisty distribution while also subtracting the value of the current optidistribution while also subtracting the value of the current optimal decision to calculate the Expected Value of Partial Perfect Information (EVPPI) [\[8;](#page-11-11) [43;](#page-12-2) [22\]](#page-11-12). The economic value of eliminating all uncertainty about ϕ (assuming risk neutrality) is equal to the EVPPI which is given by:

$$
EVPPI = \mathbb{E}_{\phi}(\max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\psi|\phi}(\text{NMB}(j, \theta_i | \text{WTP}_{\text{DALY}}, \text{WTP}_{\text{Elimination}}))) - \max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\theta}(\text{NMB}(j, \theta_i | \text{WTP}_{\text{DALY}}, \text{WTP}_{\text{Elimination}})).
$$
\n(12)

³⁰⁰ Expected Value of Sample Information (EVSI) [\[23\]](#page-11-13) mea- 301 sures the value of collecting additional data *X* to inform ϕ , assuming *X* directly updates ϕ and is independent of $\psi | \phi$. EVSI is bounded above by EVPPI. If data X were observed as x , it would update ϕ 's distribution $p(\phi|x)$, impacting the net benefit distribution for each treatment. EVSI is the average value over ³⁰⁶ all possible data sets:

$$
EVSI = \mathbb{E}_{X}(\max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\theta|X}(\text{NMB}(j, \theta_i | \text{WTP}_{\text{DALY}}, \text{WTP}_{\text{Elimination}}))) - \max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\theta}(\text{NMB}(j, \theta_i | \text{WTP}_{\text{DALY}}, \text{WTP}_{\text{Elimination}})).
$$
\n(13)

³⁰⁷ In this paper, to estimate EVSI computationally we follow the ³⁸ efficient nested Monte Carlo method based on "moment match-⁹⁹ ing" by [\[23\]](#page-11-13). The method improves computational efficiency ³¹⁰ by reducing the nested Monte Carlo error, using the moment

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

311 matching technique to approximate the distribution of the pos-362 312 terior samples more accurately (see for more details, Algorithm 363 3[1](#page--1-2)3 1 in [Appendix A\)](#page--1-1). Although, several other approaches [\[29\]](#page-11-14) 364 314 such as the Importance Sampling (IS), Regression techniques, 365 315 Gaussian approximation method and Integrated Nested Laplace366 316 Analysis (INLA) [\[22\]](#page-11-12) exist, we rely on moment matching for its 3567 317 ability to estimate EVSI for multiple alternative sample sizesses 318 with a fixed additional computational cost. We also note that 369

³¹⁹ Integrated Nested Laplace Analysis (INLA) is highly efficient 320 for performing Bayesian inference, especially in latent Gaus-370 321 sian models by treating the PSA simulations as a 'spatial prob- 371 ³²² lem' and projecting from higher to lower dimension to evaluate³⁷² ³²³ EVPPI by dimensionality reduction.

³²⁴ *2.2. Fundamental Issues using EVSI as a metric*

325 There are several challenges that arise when using the EVSI³⁷⁶ ³²⁶ metric:

327 1. Assumptions on Distributions: Implementing EVSI using

³²⁸ the moment-matching method (see Algorithm [1](#page--1-3) in Ap-₃₇₈ $_{329}$ [pendix A\)](#page--1-1) involves approximating the distribution of the $_{379}$ 330 sample information using moments (mean, variance, etc.). 331 This can introduce errors, especially if the true distribution

 332 of the sample information is not well-approximated by the 322 ³³³ moments.

 2. Dependence on Prior Information: The quality of EVSI estimates using moment matching depends heavily on the 336 prior information available. Poor or inaccurate priors can³⁸³ lead to misleading EVSI estimates.

- 338 3. Implementation Challenges: Moment matching is accu-385 ³³⁹ rate and efficient when the health economic model has a ³⁴⁰ low computation time but becomes more unfeasible as the³⁸⁷ ³⁴¹ model runtime increases and inaccurate when the sample³⁸⁸ ³⁴² size is less than 10.
- 343 4. Requires Accurate EVPPI Estimation: Moment matching³⁹⁰ ³⁴⁴ is more accurate for studies that will have significant im-³⁹¹ 345 pact on the underlying uncertainty in the decision-analytic³⁹²
- 346 model, i.e., the EVPPI of ϕ needs to be high compared to the value of reducing all model uncertainty (i.e., EVPI).
- the value of reducing all model uncertainty (i.e., EVPI), ³⁴⁸ ideally greater than 40% [\[23\]](#page-11-13).

³⁴⁹ While moment matching can be a useful tool for approxi-350 mating EVSI, these limitations must be carefully considered₃₉₆ 351 and addressed to ensure accurate and reliable health economic₃₉₇ ³⁵² decision-making.

³⁵³ 3. Linear Wasserstein Framework

 This section introduces an alternative metric to EVSI for de- termining the cost-effectiveness of intervention strategies using the Linear Wasserstein Framework (also called "Linear Opti-357 mal Transport" (LOT)) which was originally formulated in [\[55\]](#page-12-10). Wasserstein-like distances are metrics on probability measures. They can be motivated from a geometric point-of-view as they pay a cost based on rearrangement of mass. This means the dis-³⁶¹ tance is assigned (loosely speaking) based on translations. The ⁴⁰⁷

main obstacle concerning Wasserstein distances is the computational cost and a lack of off-the-shelf data analysis tools. This is where the linearisation of optimal transport distances plays an important role. The linearisation defines a map $P : \mathcal{P}(X) \to \mathbb{R}^k$ (for some *k*) such that the Wasserstein distance in $P(X)$ is ap- 2867 proximately the Euclidean distance in \mathbb{R}^k . In the Euclidean space we can easily apply several standard data analysis tools such as dimensionality reduction, classification and modelling.

3.1. Notations

Let *X*, $Y \subseteq \mathbb{R}^d$ with $\mu \in \mathcal{P}(X)$ and $\nu \in \mathcal{P}(Y)$. Given $\mu \in \mathcal{P}(X)$ and a transport map $T : X \to Y$ we can define the pushforward 373 of μ by *T* as follows.

374 Definition 1. *Let* $\mu \in \mathcal{P}(X)$ *and* $T : X \rightarrow Y$ *be a measurable as* T_{μ} *<i>andp*. *the pushforward of* μ *by T. denoted as* T_{μ} *is the measure map, the pushforward of* μ *by T, denoted as T*# μ *is the measure* ³⁷⁶ ν *defined by,*

$$
\nu(B) = \mu(T^{-1}(B)).
$$
 (14)

 377 *for all measurable set B* \subset *Y*.

3.2. Optimal Transport Formulations

Let us consider $T : X \to Y$ to be a Borel measurable function such that $T_{\#}\mu = v$. The *Monge formulation* [\[11\]](#page-11-15) would be to find the transport map *T*, given the probability measures μ , ν , minimising the objective function in $\mathbb{M}(\mu, \nu)$, where

$$
\mathbb{M}(\mu, \nu) := \inf_{T: T_{\#} \mu = \nu} \int_X |x - T(x)|^p d\mu(x). \tag{15}
$$

383 We call any *T* which satisfies $T_{\#}\mu = \nu$ a transport map and the minimizer of the optimisation problem in Eq. (15) as the the minimizer of the optimisation problem in Eq. (15) as the 385 optimal transport map T^* . It is often difficult to handle this non-convex optimisation problem in Eq. [\(15\)](#page-4-1) due to its nonlinearity in *T*.

We define the set $\Pi(\mu, \nu)$ of couplings between measures μ and ν to be the set of probability measures on the product space $P(X \times Y)$ whose first marginal is μ and the second marginal is ν . For any transport map *T*: $X \rightarrow Y$, there exists an associated transport plan π such that,

$$
\pi = (\mathrm{Id} \times T)_{\#}\mu. \tag{16}
$$

393 where Id denotes the identity map. We recall that if P^X : X \times $Y \rightarrow X$ and $P^Y : X \times Y \rightarrow Y$ are the canonical projections, then the marginals are $P_{\#}^X \pi = \mu$ and $P_{\#}^Y \pi = \nu$.
The *Kantorovich formulation* [11] we

The *Kantorovich formulation* [\[11\]](#page-11-15) would be to minimise the S397 objective function $\mathbb{K}(\mu, \nu)$, given the probability measures μ , ν , s98 where

$$
\mathbb{K}(\mu, \nu) := \inf_{\pi \in \Pi(\mu, \nu)} \int_{X \times Y} |x - T(x)|^p \, \mathrm{d}\pi(x, y). \tag{17}
$$

The minimizer of Eq. [\(17\)](#page-4-2) is the optimal transport plan π^* . In this sense the *Kantorovich formulation* in Eq. (17) can viewed ⁴⁰⁰ this sense, the *Kantorovich formulation* in Eq. [\(17\)](#page-4-2) can viewed ⁴⁰¹ as a relaxation of the *Monge formulation*. The difficulty in proving the existence of maps that satisfy the constraint $T_{\mu}\mu = \nu$ leads to mass splitting during transportation, especially in cases involving discrete measures where such transport maps may not be feasible. This modified formulation in Eq. [\(17\)](#page-4-2) now describes the amount of mass $\pi(x, y)$ that can be transported from x to different positions at *y*.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

⁴⁰⁸ *3.3. Wasserstein Distances*

⁴⁰⁹ We denote the space of probability measures on *X* that have⁴³⁹ f_{410} finite p^{th} moment, as follows:

$$
\mathcal{P}_p(X) := \Big\{ \mu \in \mathcal{P}(X) : \int_X |x|^p \, d\mu(x) < +\infty \Big\}.
$$

411 So, when *X* is bounded $\mathcal{P}_p(X) = \mathcal{P}(X)$. This allows us to 412 define the *p* − Wasserstein distance [\[11\]](#page-11-15), which is the minimum₄₄₄ ⁴¹³ transportation cost between μ and ν , as

$$
d_{W^p}(\mu, \nu) = \begin{cases} \inf_{\pi \in \Pi(\mu, \nu)} \left(\int_{X \times Y} |x - y|^p \, d\pi(x, y) \right)^{\frac{1}{p}} & \text{for } 1 \le p < \infty, \\ \inf_{\pi \in \Pi(\mu, \nu)} \pi - \text{ess sup}_{(x, y)} |x - y| & \text{for } p = \infty. \end{cases} \tag{18}^{445}
$$

 414 The d_{W_P} distances are advantageous for Lagrangian modeling⁴⁴⁷ 415 due to their simplicity, metric properties (like symmetry), exis-448 416 tence of geodesics, Riemannian structure and theoretical bene-449 417 fits like existence of optimal transport maps and plans. How-450 418 ever, they require the inputs to be probability measures, are⁴⁵¹ 419 computationally expensive, and there is a lack off-the-shelf data⁴⁵² 420 analysis tools. We therefore opt for the Linear p -Wasserstein⁴⁵³ ⁴²¹ Framework.

⁴²² *3.4. Linear Wasserstein Framework*

Figure 1: The Linear *p*-Wasserstein framework embeds measures in the tangent space of a fixed reference σ . As a consequence, the Euclidean distance between the non-negative measures u and v is an approximation for the 2-Wasserstein the non-negative measures μ and ν is an approximation for the 2-Wasserstein
distance $d_{\text{tot}}(\mu, \nu)$. This figure is computed using ParaView distance $d_{W^2}(\mu, \nu)$. This figure is computed using ParaView.

423 The Linear p-Wassertein framework introduced by Wang in⁴⁶⁶ 424 [\[55\]](#page-12-10), illustrated in Figure [1,](#page-5-0) has several applications in biomedi- 470 425 cal imaging, analysis of 2-D point cloud data [\[5;](#page-11-16) [36\]](#page-12-11), telescopic⁴⁷¹ 426 and facial expressions [\[32;](#page-12-12) [31\]](#page-12-13). The term "linear" refers to the 472 427 (Euclidean) vector space structure that one gains after approx- 473 428 imation. The method linearizes the Wasserstein distance by 474 429 computing the projection to tangent space at a fixed reference. ⁴³⁰ To discuss the Linear p−Wasserstein framework in the con-431 tinuous setting we consider a domain *X* ∈ \mathbb{R}^d that is a bounded, ⁴³² convex and closed subset of \mathbb{R}^d with a non-empty interior, 433 alongside the probability measures $\mu_i \in \mathcal{P}(X)$ $\forall i \in \{1, 2, \dots, N\}^{479}$ and a fixed reference $\sigma \in \mathcal{P}(X)$. The optimal transport map T_i^*
hetween σ and μ , satisfies 434 435 between σ and μ_i satisfies,

$$
d_{W^p}(\mu_i, \sigma) = \left(\int_X |x - T_i^*(x)|^p \, d\sigma(x)\right)^{\frac{1}{p}} \tag{19}_{48}
$$

where $T_{\mu\nu}^* \sigma = \mu_i$. This provides the basis to formally introduce
the linear Wasserstein distance for two measures say μ_1 and μ_2 437 the linear Wasserstein distance for two measures say μ_1 and μ_2 .

$$
d_{LOT_{WP}}(\mu_1, \mu_2, \sigma) = \left(\int_X |T_1^*(x) - T_2^*(x)|^p \mathrm{d}\sigma(x)\right)^{\frac{1}{p}}.\tag{20}_{\text{495}}
$$

⁴³⁸ This enables us to compute the linear embeddings in the form $_{449}$ of projections $P : \mathcal{P}(X) \to T_{\sigma} \mathcal{P}(X)$ which are the velocity maps from the manifold to the tangent space. This can be expressed from the manifold to the tangent space. This can be expressed ⁴⁴¹ as,

$$
P(\mu_i) = T_i^* - \text{Id},\tag{21}
$$

 $_{442}$ Equivalently, relating the Linear Wasserstein distance $d_{LOT_{WP}}$ to p -Wasserstein distance d_{W^p} in equation [\(19\)](#page-5-1) we can rewrite as follows.

$$
d_{W^p}(\mu_i, \sigma) = ||P(\mu_i) - P(\sigma)||_{L^p(\sigma)} = d_{LOT_{WP}}(\mu_i, \sigma, \sigma). \tag{22}
$$

Remark 2. This implies that the maps $P(\mu_i)$ form the linear embeddings in the form of projections from the p-Wasserstein 447 space to L^2 (Euclidean) space, thereby preserving the optimal transport distance between μ_i and σ . It is assumed that $d_{\text{LOT}_{\text{WP}}}(\mu_1, \mu_2, \sigma) \approx d_{\text{WP}}(\mu_1, \mu_2)$ and the approximation depends ⁴⁵⁰ on the curvature of the Wasserstein space and in general the linear Wasserstein distance is not equivalent (in terms of metric equivalence) to the Wasserstein space. However, when there is some special structure, such as when the measures are all trans-lations or shearings then one gets established bounds [\[10\]](#page-11-17) like 455 *cd*_{LOT_W} (μ_1, μ_2, σ) $\leq d_{W}$ (μ_1, μ_2) $\leq C d_{\text{LOT}_{W}^p}(\mu_1, \mu_2, \sigma)$ where c , *c*, *c* are some positive constants. ⁴⁵⁶ *^c*,*^C* are some positive constants.

⁴⁵⁷ *3.5. Advantages of using the Linear Wasserstein Framework*

 The linear optimal transport (LOT) framework offers an al- ternative approach to the calculation of the Expected Value of Sample Information (EVSI), addressing several limitations as-sociated with the moment matching method as outlined below:

- ⁴⁶² 1. Approximation Accuracy: Unlike moment matching, ⁴⁶³ which approximates the distribution using moments, LOT ⁴⁶⁴ can directly handle the full distribution of the data by us-Figure 1: The Linear p-Wasserstein framework embeds measures in the tangentales in g the probability measures. This leads to more accurate space of a fixed reference σ . As a consequence, the Euclidean distance between representations of the underlying distributions, reducing approximation errors. According to ISPOR's recommen-⁴⁶⁸ dations [\[39\]](#page-12-14), uncertainty in parameter input values should be characterized using probability distributions. Additionally, any dependencies between parameters should be represented by a joint, correlated probability distribution. We have modeled these inputs as a point cloud (discrete set of points in space).
	- 2. Handling High Dimensions: The LOT framework provides linear projections that help reducing the dimensionality from the ambient to the tangent space after applying off-the-shelf data analysis tools.
	- 3. Distributional Assumptions: LOT does not rely on the assumption that the distribution can be adequately described by expectation and variance. It considers the entire distribution suitable for handling non-linearities and inter-⁴⁸² actions inherent in the data, thus accommodating higher-³⁸ order moments more naturally by preserving salient properties of the data and accounting structural uncertainty.
		- 4. Independence from Prior Information: The LOT approach minimizes this dependency by utilizing an empirical distribution derived from observed data. This empirical focus means that the approach is less susceptible to the biases introduced by incorrect prior assumptions.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 By directly addressing the distribution of sample informa-491 tion and leveraging efficient optimization techniques, the LOT₅₄₅ framework provides a robust and scalable uncertainty quantifi- cation tool to calculate cost-effectiveness analysis. This circum-494 vents many of the limitations associated with moment match-548 ing, leading to more accurate and reliable decision-making.

4. Methods

 497 We utilize the stochastic TRANSFIL model [\[25\]](#page-11-18) with pa- 554 498 rameters previously estimated $[26; 45]$ $[26; 45]$ to represent transmis- $_{555}$ 499 sion by Culicine mosquitoes (for more details on the param-556 500 eters refer Table [C.14](#page--1-4) in [Appendix C\)](#page--1-1). The model simulates₅₅₇ $_{501}$ the health impacts of lymphatic filariasis (LF) and incorporates ⁵⁰² mass drug administration (MDA) effects, based on simulated ⁵⁰³ target coverage, systematic nonadherence, and drug efficacy ⁵⁰⁴ [\[18\]](#page-11-20). We excluded other interventions such as vector control ⁵⁰⁵ for this study. We modeled closed populations of 100,000- ⁵⁰⁶ 500,000 people, reflecting EU sizes in standard TAS surveys 507 per WHO guidelines [\[54\]](#page-12-5). The detection parameters were fitted⁵⁶³ ⁵⁰⁸ using Bayesian MCMC to data from Malindi, Kenya, Colombo, ⁵⁰⁹ Gampaha and Sri Lanka [\[26\]](#page-11-19). MDAs were simulated at 65% ⁵¹⁰ and 80% coverage. Systematic non-adherence was included by 511 calculating individual treatment probabilities based on coverage 512 and between-round correlation, parameterized with data from ⁵¹³ Leogane, Haiti, and Egypt [\[18\]](#page-11-20).

⁵¹⁴ The model also simulates health impacts of lymphoedema,⁵⁷⁰ hydrocele, and acute adenolymphangitis (ADL) using pub-516 lished methods. Morbidity due to lymphoedema and hydrocele was modeled with data from India [\[13\]](#page-11-21). The model assumes morbidity occurs after accruing a certain cumulative worm bur- $\frac{1}{519}$ den. ADL incidence was estimated twice per year in 70%⁵⁷⁵ of hydrocele patients and four times annually in 95% of lym-521 phoedema patients [\[14\]](#page-11-22). Prevalence was converted using pub-⁵⁷⁷ 522 lished disability weights [\[21\]](#page-11-23). Side-effects of MDA were not⁵⁷⁸ considered, despite reports of 13% feeling unwell post-MDA, as these effects were deemed minor [\[59\]](#page-12-16). Mental illness was also excluded due to lack of accurate data, despite its recog-nized burden in LF [\[49;](#page-12-17) [30\]](#page-12-18).

For WHO-prescribed starting and stopping decisions [\[54\]](#page-12-5),⁵⁸³ we considered TAS surveys from 30 sites per EU. Baseline prevalences were sampled from a normal distribution with means of 5-10%, 10-20%, or 20-30%. In each site, we sam- $_{531}$ pled 40-60 adults aged 20 years to evaluate TAS. If mf-positive⁵⁸⁷ 532 adults were below the stopping threshold MDA was halted un-588 til the next survey; otherwise, it continued. We iterated this algorithm 1,000 times and reported mean baseline prevalences. Cost simulations considered TAS surveys (\$12,494.75 [\[7\]](#page-11-24)) and MDA rounds (\$7,640.92 [\[47\]](#page-12-19)) over a 20-year horizon, with dis- counting included. We note that for MDA restarts, the costs of 593 the MDA and TAS are doubled.

⁵³⁹ For cost-effectiveness analysis, using the Expected Incre-⁵⁴⁰ mental Net Monetary Benefit (EINMB) metric, we used <1% m f prevalence in children (aged 5 years and above) as the com- 597 ⁵⁴² parator. We simulated transmission dynamics and morbidity 543 associated with LF, including DALY burden for 30 sites and 599

a TAS-like survey across those sites. We investigated different MDA coverages (65% and 80%) and different baseline LF prevalences. We evaluated WTP_{DALY} for DALYs averted, reflecting opportunity costs and adjusted for purchasing power parity [\[51\]](#page-12-20) using \$500 (Ghana), \$2,500 (Congo) and \$5,000 ⁵⁴⁹ (Southern Africa) based on the provided country-specific per-⁵⁵⁰ centage of GDP per capita estimate that underlies the DALY-⁵⁵¹ 4 estimation method by multiplying the total per individual ⁵⁵² DALY value times a specific proportion of the GDP per capita 553 [\[35\]](#page-12-1) for LMIC and WTP_{Elimination} per unit increase in local elim-ination ranging from \$0-\$10,000 [\[2\]](#page-11-10). We evaluated different stopping thresholds for Culicine transmitters using a modelbased transmission dynamics, health, and economic impacts. To address our key questions, we examined:

- ⁵⁵⁸ 1. Probability of elimination [\[46\]](#page-12-21), i.e., the probability of achieving local elimination within 20 years post-MDA if ϵ_{560} mf prevalence in a sample of <1,700 adults aged ≥ 20 years was below the stopping threshold.
	- 2. Health impact evaluation through DALYs averted for morbidity by quantifying the overall disease burden due to lymphoedema, hydrocele and ADL by the years lived with disability. In this context, we assume that the years of life lost due to premature death is zero as death due to LF is rare.
- ⁵⁶⁸ 3. Costs due to MDA rounds and TAS surveys.
- ⁵⁶⁹ 4. Computing the cost-effectiveness of lowering the stopping 570 threshold to <0.5% in adults with the help of the EINMB metric (see Section 2). We note that for this metric we metric (see Section [2\)](#page-2-0). We note that for this metric we use the fixed country-specific WTP_{DALY} and vary across an approximate range of WTP_{Elimination}.
	- 5. Evaluating the uncertainty in parameters (total costs, DALYs averted and/or probability of elimination) using Value of Information (VoI) methodology, with EVSI met-ric (see Section [2\)](#page-2-0) implemented using moment matching method (see Algorithm [1](#page--1-3) in [Appendix A\)](#page--1-1).
- 6. Evaluating the uncertainty in parameters (total costs, DALYs averted and/or probability of elimination) using the Linear Wasserstein Framework in conjunction with LDA (see Section [3\)](#page-4-0). The total costs due to MDA rounds and TAS surveys, along with DALYs averted and probability of elimination, are represented as probability mea-⁵⁸⁵ sures on point cloud data (discrete set of data points in space). Let μ_i denote the empirical measure associated with the *i*-th point cloud, defined as: $\mu_i = \frac{1}{m_i} \sum_{j=1}^{m_i} \delta_{x_j} \delta_{x_j}$ 588 where x_j ∈ \mathbb{R}^d and m_i denotes total data points in each μ_i . We sample the point clouds so that each point cloud

has the same fixed number $m = 1000$ data points, i.e. μ_i . We sample the point clouds so that each point cloud $\mu_i = \frac{1}{m} \sum_{j=1}^m \delta_{x_j^{(i)}}$ (up to relabelling of the $\tilde{x}_j^{(i)} \in \mathbb{R}^d$) f_{592} for $i = \{1, 2, \cdots, N\}$ and $j = \{1, 2, \cdots, m\}$. Following this, we compute the projections $P(\mu_i)$ as defined in Eq.

(21) for each measure μ_i . Using these projections, firstly ⁵⁹⁴ [\(21\)](#page-5-2) for each measure μ_i . Using these projections, firstly
 μ_i we apply PCA to obtain the eigenvectors that accounts we apply PCA to obtain the eigenvectors that accounts for principle variations of the distributions. We then use these projected eigenvectors from PCA as feature vectors $\sum_{i=1}^{598}$ (denoted as $\{X_i\}_{i=1}^L$) along with three classes of baseline prevalences $(5-10\%, 10-20\%, 20-30\%)$ as labels (denoted

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Figure 2: Simplified timeline plots for a single population of size 1000 for 10 simulations illustrating the model-predicted temporal trends in mf prevalence (solid red lines), DALY burden are computed as the morbidity prevalence of lymphoedema, hydrocele and acute adenolymphangitis (dashed blue lines) times the disability weights [\[21\]](#page-11-23) and cumulative wormburden (dotted green lines) for 5-10% mf prevalence using (a) <0.5%, (b) <1%, (c) <2% and (d) <5% as the stopping threshold criteria for TAS with 80% MDA coverage for a sample of adults.

Figure 3: Epidemiological outcomes for different mf stopping threshold preva-625 lences for TAS with 5-10% baseline prevalence with 80% MDA coverage of₆₂₆ different age-groups of the eligible population post-surveillance. Here, we represent the mean outcomes by randomly sampling approximately 30 sites with ⁶²⁷ 40-60 people strafied by age per site to replicate the characteristics of an evaluation unit (EU, \lt 500,000 people). Note that costs and DALYs averted are egg normalized to the same scale for improved visualization in the plots. normalized to the same scale for improved visualization in the plots.

 $\{y_i\}_{i=1}^L$ where *L* is the size of training dataset used as $\frac{601}{602}$ inputs for LDA [\[58\]](#page-12-22) to classify the <0.5% mf threshold⁶³³ for different baseline prevalences relative to the reference.⁶³⁴ for different baseline prevalences relative to the reference.⁶³⁴ 603 We note that we train the LDA on 80% of the feature vec-635 ⁶⁰⁴ tor and labels (iteratively) and make predictions on the re-605 maining 20% of the unseen feature vector and labels. In⁶³⁷ ϵ_{06} this study, we use the fixed WTP $_{\text{DALY}}$ as outlined above⁶³⁸ 607 and estimate the range for WTP_{Elimination} (see Algorithm [2](#page--1-5)639 ⁶⁰⁸ in [Appendix A](#page--1-1) for more details)

⁶⁰⁹ 5. Results

⁶¹⁰ The impact of MDA on the interruption of LF transmission⁶⁴⁴ ⁶¹¹ and reduction of the disease burden using DALYs is dependent₆₄₅

Number of MDA rounds 612 On the threshold criteria defined for passing the TAS, as illus-
(Number of TAS surveys)₆₁₃ trated in the example of a setting with a baseline prevalence of trated in the example of a setting with a baseline prevalence of ⁶¹⁴ 5-10% and 80% MDA coverage of a single population size of 615 1000 for 10 simulations (Figure [2\)](#page-7-1).

> ⁶¹⁶ In Figure [3](#page-7-2) (circles) replicating the characteristics of an EU, ⁶¹⁷ we find that the probability for local elimination at 5-10% 618 baseline prevalence with 80% MDA coverage and a threshold 619 of <0.5% mf prevalence was 89.2% (\geq 5 years), 91.8% (\geq 20 years), and 90.72% (entire eligible population). For a threshold years), and 90.72% (entire eligible population). For a threshold 621 of <1% mf prevalence, it was 80.05%, 83.8%, and 81.76%, respectively. Lowering the threshold increases the probability for spectively. Lowering the threshold increases the probability for ⁶²³ local elimination across different prevalences, coverages, and ⁶²⁴ age-groups. These trends follow across different baseline preva-lences, MDA coverages and treatment strategies (refer [B.1,](#page--1-6) [B.2,](#page--1-7) and [B.3](#page--1-8) in [Appendix B\)](#page--1-1).

> Additionally in Figure [3](#page-7-2) (triangles), a lower threshold results in fewer MDA rounds and surveys due to reduced probability of restarting after stopping, hence lower costs. However, for the lowest baseline prevalence, restarting MDA is unlikely for ei-⁶³¹ ther threshold for children and adults, with slightly higher costs for the lower threshold due to extra rounds needed. For the entire eligible population, higher threshold costs are greater due to MDA restarts. In general, more restarts occur at higher baseline prevalences and lower MDA coverage for all thresholds due to the stochastic nature of the model dynamics accounting for higher transmission and increased treatment rounds to achieve elimination (refer Tables [B.4](#page--1-9), B.5 and [B.6,](#page--1-11) in [Appendix B\)](#page--1-1).

> Figure [3](#page-7-2) (squares) shows mean DALYs averted across differ-640 ent thresholds for 80% MDA coverage. Lowering the threshold ⁶⁴¹ results in more DALYs averted due to a reduction in worm bur-642 dens. Trends are similar for 65% MDA coverage. The choice ⁶⁴³ of threshold depends on epidemiological context and economic considerations, including WTP_{DALY}.

To evaluate costs, health impact, and monetization benefits

Figure 4: a. EINMB based on the WTP for range of DALY averted for morbidity: \$500 (green), \$2500 (red), \$5000 (blue) for 5-10% (circles), 10-20% (triangles) and 20-30% (squares) baseline prevalence for a sample of adults. b. EINMB based on the WTP for 1% increase in probability of elimination from \$0-\$10,000 and the WTP_{DALY}: \$500 (green), \$2500 (red), \$5000 (blue) for sample of adults for (i) $5-10\%$ - circles (ii) $10-20\%$ - triangles (iii) $20-30\%$ - squares baseline prevalences comparing <0.5% threshold in a sample of adults with respect to <1% threshold of mf prevalence in children (comparator).

 of local elimination, we use expected incremental net mone-647 tary benefit (EINMB). Higher EINMB indicates optimal cost-677 648 effectiveness at a given WTP_{DALY}. Our findings (Figure [4a](#page-8-0))⁶⁷⁸ 649 show that at 80% coverage, switching to a lower threshold₆₇₉ is cost-effective across all baseline prevalences, keeping costs per DALY averted below national WTP thresholds (positive EINMB). Variability in results is due to demographic factors such as age, treatment strategy, and population growth [\[40\]](#page-12-23). At 65% coverage (Figure [4b](#page-8-0)), more rounds and surveys suggest 655 switching to a lower threshold is cost-effective based on WTP685 per 1% increase in local elimination probability, aligning with GPELF goals (refer Tables [B.7,](#page--1-12) [B.8](#page--1-13) in [Appendix B\)](#page--1-1). For WTPs 658 of approximately \$4200, \$3000, and \$1000 per 1% increase inses local elimination for different baseline prevalence, switching is recommended (Figure [4b](#page-8-0), black solid line).

 $_{661}$ Health economic decision-analytic models are used to esti- $_{691}$ 662 mate the expected net benefits of competing decision options.⁶⁹² 663 The true values of the input parameters of such models are⁶⁹³ 664 rarely known with certainty, and it is often useful to quantify⁶⁹⁴ 665 the value to the decision maker of reducing uncertainty through⁶⁹⁵ collecting new data. In the context of understanding how to⁶⁹⁶ 667 measure the prevalence for different stopping threshold with⁶⁹⁷ ⁶⁶⁸ precision, we need a handle to quantify uncertainty revolving 669 around the costs due to MDA rounds and surveys alongside⁶⁹⁹ 670 DALYs averted and unit increase in probability of elimination.⁷⁰⁰ 671 In this light, the value of the proposed research design for ev-⁷⁰¹ 672 ery additional sample size can be quantified by the EVSI metric⁷⁰² 673 as defined in Section [2.](#page-2-0) In Figure [5](#page-9-1) (a)-(b), we find that the⁷⁰³ 674 EVSI peaks around a WTP_{Elimination} of \$2,500-\$3,000 (max) for⁷⁰⁴ $675 <$ <0.5% and <1% stopping threshold. On the other hand, for Fig-705

in 0.5% than 5%) in lower stopping thresholds is more beneficial to account for uncertainty quantification of MDA stopping decisions as justified for 5-10% baseline prevalence. Ad-ditionally, in Tables [B.11,](#page--1-14) [B.12](#page--1-15) and [B.13](#page--1-16) (see [Appendix B\)](#page--1-1). we find that moment matching is much faster than the benchmark nested Monte-Carlo method, although both converge to the same EVSI at larger sample sizes. Figure [5](#page-9-1) illustrates the theoretically established trend in the fact that the EVSI (dark blue lines) approached the EVPPI (thick dark blue line below EVPI) as defined in Section [2](#page-2-0) at larger sample sizes, indicating ⁶⁹⁰ that the value of information gained from larger studies may approach the theoretical maximum value of removing the uncertainty of reaching elimination based on the different thresholds. In order to further test the robustness of the MDA stopping decision based on the cost-effectiveness of lower stopping threshold $(< 0.5\%$ mf prevalence in adults), we rely on the Linear Wasserstein Framework in conjunction with PCA and LDA. In Figure [6a](#page-9-2), we find the scattergram of the costs with DALYs averted with 80% MDA coverage for different baseline prevalences (represented as circles, triangles and squares) show that the lower stopping thresholds $(< 0.5\%)$ are cost-effective using the fixed country-specific WTP $_{\text{DALY}}$ ranging from \$500-\$5,000 when predicted on the unseen 20% of the feature vector (test sample). Each symbol represents the mean incremental costs to incremental DALYs averted to obtain a standardized compar-ison to the EINMB metric in Figure [4a](#page-8-0). Likewise, in Figure

ure [5](#page-9-1) (c)-(d) we see that the EVSI peaks around a $WTP_{Elimination}$ of about \$1,500-\$1,700 (max) for $< 2\%$ and $< 5\%$. This corresponds to the fact that additional information obtained from extra EVSI per person (illustrated in Figure [5](#page-9-1) by higher peaks

Figure 5: EVSI implemented using the moment matching method for different thresholds (a: <0.5%, b: <1%, c: <2% and d: <5%) to evaluate the uncertainty related to the cost-effectiveness of different stopping threshold for TAS under a range of WTP per unit increase in elimination for 5-10% baseline prevalence in a sample of adults with 65% MDA coverage.

Figure 6: Summary figure illustrating the variations in the cost-effectiveness of the lower threshold for TAS using the Linear Wasserstein framework by considering the total costs and DALYs averted, probability for elimination as inputs. The LOT embeddings are projected into a lower-dimension space using PCA and this reduced feature vector from PCA is trained using LDA (80:20 split) for classifying <0.5% threshold at different baseline prevalence (labels) depicted as (circles) 5-10%, (triangles) 10-20% and (squares) 20-30% alongside the WTP for DALY averted for morbidity: \$500 (green), \$2,500 (red), \$5,000 (blue) for a sample of adults. a. Scattergram of incremental costs and DALYs averted for 80% MDA coverage b. Scattergram of incremental costs and unit increase in probability of elimination for 65% MDA coverage c. EVSI per person for the estimated optimum WTP per unit increase in elimination. Note: The comparator chosen as the reference template is <1% mf prevalence as the stopping threshold for TAS in children. The ellipses estimated from the covariance matrix and the mean vectors of each baseline prevalence (class labels) denote the 95% confidence intervals accounting for the uncertainty and variability within the distribution of each class. Each symbol represents the mean of the incremental costs to DALYs averted or probability of elimination classified by their respective baseline prevalences.

 [6b](#page-9-2). we find the scattergram of the costs with DALYs averted in addition to the probability of elimination show when $\lt 0.5\%$ respectively stopping thresholds are cost-effective with a narrower estimated respectively stopping thresholds are cost-effective with a narrower estimated₇₂₉ WTPElimination per unit increase in the probability of elimina- tion from \$500-\$3000 for 65% MDA coverage when predicted on the unseen 20% of the feature vector (test sample). Simi- larly, each symbol here represents the mean incremental costs to incremental probability for elimination to obtain a standard- ized comparison to the EINMB metric in Figure [4b](#page-8-0). We re- mark that the results illustrated in Figure [6](#page-9-2) a and b were com-⁷¹⁶ puted using Step 1-3 of Algorithm [2](#page--1-5) with 80% training sample₇₃₆ size. Finally, in Figure [6c](#page-9-2), we illustrate the EVSI per person using the utility gained from additional information predicted from LDA (see Algorithm [2](#page--1-5) for more details) with the optimum 720 WTP_{Elimination} estimated. We observe that as baseline preva-739 lence decreases, the optimum WTP $_{Elimination}$ to make the lower $_{740}$ stopping threshold cost-effective increases due to more addi- tional benefits gained from elimination and DALYs averted as demonstrated in Figure [3.](#page-7-2) Consequently, in Tables [B.9](#page--1-17) and [B.10](#page--1-18) $_{743}$ (refer to Supplementary [Appendix B\)](#page--1-1), we present the classifi- 744 cation error for accurately predicting the baseline prevalences

(class labels) for different stopping thresholds which decreases as training sample sizes increase. This improvement enhances the power of the utility function, which reflects the additive ben-⁷³⁰ efits gained with varying stopping thresholds, as indicated by the EVSI metric. This effect is achieved by training the LDA classifier with different fractions of the sample sizes, demonstrating that larger training datasets lead to more accurate classifications and thus greater potential benefits from additional data.

6. Discussion

The probability of local elimination is determined by stopping thresholds, which are crucial for many disease control policies. That being said, it would be worthwhile to look into the effects of a lower threshold on program costs overall as well as whether it raises the likelihood of local elimination. The ap-plication of such a lower threshold in China [\[57\]](#page-12-24) and its significance in effective LF control serve as examples of the potential advantages of a lower threshold, which this study highlights. However, the GPELF can use this example to gather crucial

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

⁷⁴⁶ data in order to establish standards for assessing whether MDA ⁷⁴⁷ has been successful in bringing the infection prevalence down ⁷⁴⁸ to a point where recrudescence is unlikely to happen.

749 As we reduce the mf prevalence threshold from $\langle 1\% \rangle$ to₈₀₆ $\langle 0.5\% \rangle$, the likelihood of local elimination increases, accord-say $750 \le 0.5\%$, the likelihood of local elimination increases, accord- 807
 751 ing to our analysis of the effects of various stopping thresholds ing to our analysis of the effects of various stopping thresholds. for TAS across 30 sites. Diminished DALY burden and restart probability are mitigated by a lower threshold, despite requir- ing more rounds. Employing the defined EINMB metric for CEA reveals that switching to a lower threshold is economical at 80% MDA coverage. However, for 65% MDA coverage, ex-757 tra benefits are needed, such as utilizing the WTP_{Elimination} per₈₁₄ unit increase for elimination. The low amount of data, espe- cially on systematic non-adherence and wider disease impacts like mental illness, is the reason for the conservative morbidity estimates [\[49;](#page-12-17) [30\]](#page-12-18).

 The expanded use of CEA in healthcare faces several chal- lenges. First, decision-makers must account for social concerns like prioritizing the sick, reducing health disparities by inte- grating more social concerns into CEA techniques. Second, current CEA practices, focused on evaluating new strategies or technologies, often overlook signs of resource misallocation. Third, assessing the broad range of interventions needed for CEA to improve allocative efficiency can be prohibitively ex- pensive and time-consuming. Additionally, many CEA studies produce context-specific results, limiting their applicability to s_{28} different populations. Progress towards providing timely, af- fordable information on the costs and effects of various inter- ventions remains limited, particularly for LMIC [\[48;](#page-12-0) [60\]](#page-12-25). On the other hand, the Linear Wasserstein Framework de- spite being mathematically rigorous has its own limitations. 777 Firstly, the framework makes several modelling assumptions.₈₃₄ Namely, that the distance should be proportional to the cost of $_{835}$ translations. This can make the distance sensitive to outliers. Secondly, the Linear Wasserstein distance is also an approxi- mation of the Wasserstein distance and this approximation may deteriorate depending on the local curvature. Thirdly, being balanced, this framework requires equal number of datapoints (1000) for each probability measures derived from each of the 388 pointcloud data for the different baseline prevalences (classes) which can disproportionately affect the robustness of the re- sults, if class-imbalance exists. A further extension to this framework could be to generate future projections of the model simulations for different baseline prevalences using fewer runs to save the computational power of the TRANSFIL model from a Bayesian perspective [\[37\]](#page-12-26) or use state-of-art methods such as 842 graph-based semi-supervised methods [\[9\]](#page-11-25) that can leverage the advantages of this geometric embedding when very little infor- mation on the data is provided so that it can learn the geometry of the underlying point cloud data effectively.

⁷⁹⁶ Our study assumes constant survey implementation costs, ⁷⁹⁷ excluding potential out-of-pocket expenses and future cost ⁷⁹⁸ changes [\[41\]](#page-12-27). Despite challenges in estimating precise costs ⁷⁹⁹ for MDA and TAS due to incomplete records and data access issues, simulations help understand the TAS threshold's im-851 801 pact on stopping MDA. A limitation in this study is the exclu-852 802 sion of vector control benefits, which remain debated. Whilessa

some studies suggest combined MDA and vector control benefits in low endemic regions, others find no added advantage over ⁸⁰⁵ MDA alone upon which further research is needed. Another major limitation is that our modelling study relies on *Culex* vector due to its increased efficiency in transmission. Although direct implication of *Culex* species in the transmission of LF in West and Central Africa is still not well documented [\[42;](#page-12-28) [4\]](#page-11-26), in ⁸¹⁰ East Africa, *Culex* species particularly *Cx. quinquefasciatus* is known to have a major role in LF transmission [\[17;](#page-11-27) [33\]](#page-12-29). With changing climate associated to increased traffic between East and West African countries and rapid expansion of this species in urban settings, it is becoming crucial to assess the role of *Culex* species in the transmission of diseases like LF. We also restrict our analysis to the IA drug, but studies [\[50\]](#page-12-30) for oncho have found that IA may not lead to elimination of transmis-818 sion (EoT) in all endemic areas and moxidectin-based strategies could accelerate progress toward EoT and reduce programmatic delivery costs compared with ivermectin-based strategies. We also note that the use of the three-drug combination IDA, has particular challenges [\[45\]](#page-12-15) for survey design due to reductions in mf density but not Ag over one or two rounds of treatment $[27]$.

Despite these drawbacks, our research emphasizes how important it is to choose the right framework for uncertainty quantification when making decisions, especially when it comes to disease interventions, particularly LF. It is also essential to comprehend the dynamics of local elimination post-threshold crossing and how it interacts with LF interventions. Our research in-831 dicates that although there is a long transient phase involved in the path to LF local elimination post-MDA surveillance, lower thresholds may help programs achieve their objectives. In addition, we also propose the need for better framework to quantify the uncertainty inherent in the model parameters to analyze the cost-effectiveness of lowering the stopping threshold in LF.

7. Competing interests

The authors declare no competing interests.

8. Funding

MCAO, MG and TDH were supported by funding from the Bill & Melinda Gates Foundation (INV-030046), via the NTD Modelling Consortium. TDH is supported by funding from the Li Ka Shing Foundation at the Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford. MT would like to acknowledge the support of the 846 Leverhulme Trust Research through the Project Award "Robust" Learning: Uncertainty Quantification, Sensitivity and Stability" (grant agreement RPG-2024-051) and the EPSRC Mathematical and Foundations of Artificial Intelligence Probabilistic AI Hub (grant agreement EP/Y007174/1). LP gratefully acknowledges funding from the Wellcome Trust and Royal Society Sir Henry Dale Fellowship $(202562/Z/16/Z)$, the Wellcome Trust Discovery Award "Harnessing epidemiological and

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

genomic data for understanding of respiratory virus transmis-914 855 sion at multiple scales" (227438/Z/23/Z) and the UKRI Im-915 856 pact Acceleration Award (IAA 386). KBP is supported by the⁹¹⁶ 857 Medical Research Foundation (MRF-160-0017-ELP-POUW-918 858 C0909). MCAO acknowledges the receipt of funding obtained 919 859 from the Health Data Research UK-The Alan Turing Insti-920 860 tute Wellcome (Grant Ref: 218529/Z/19/Z) and the Cambridge $\frac{921}{922}$ 861 Trust scholarship from the Commonwealth European and In- $_{923}$ 862 ternational Trust (CCEIT). The funders had no role in study de-924 863 sign, data collection and analysis, decision to publish, or prepa-925 ⁸⁶⁴ ration of the manuscript.

9. CRediT authorship contribution statement

Mary Chriselda Antony Oliver: Conceptualization, Method-932 867 ology, Software, Formal analysis, Writing-original draft, 334 868 Writing-review and editing, Visualization. Matthew Graham:935 869 Software, Writing- review and editing. Ioanna Manolopoulou, 936 870 Graham F. Medley, Lorenzo Pellis - Writing- review and⁹³⁷ 871 editing. Koen B Poewels, Matthew Thorpe, T. Deirdre 872 Hollingsworth - Conceptualization, Methodology, Writing - re-940 873 view and editing, Supervision.

874 References

- 875 [1] Anderson, R.M. and May, R. (1992) Infectious Diseases of Humans: Dy-₉₄₇ 876 namics and Control of (Paper Backed) Oxford. Oxford University Press, 948 ⁸⁷⁷ New York.
- 878 [2] Antillon, Marina et al. "Economic evaluation of disease elimination:₉₅₀ 879 An extension to the net-benefit framework and application to human₉₅₁ 880 African trypanosomiasis." Proceedings of the National Academy of Sci-₉₅₂ ences of the United States of America vol. 118,50 (2021): e2026797118. ⁸⁸² doi:10.1073/pnas.2026797118.
- 883 [3] Antony Oliver, Mary Chriselda et al. "Reducing the Antigen Prevalence₉₅₅ 884 Target Threshold for Stopping and Restarting Mass Drug Administration₉₅₆ 885 for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness₉₅₇ 886 Simulation in Tanzania, India and Haiti." Clinical infectious diseases : 958 887 an official publication of the Infectious Diseases Society of America vol.₉₅₉ ⁸⁸⁸ 78,Supplement 2 (2024): S160-S168. doi:10.1093/cid/ciae108
- 889 [4] Appawu, M A et al. "Lymphatic filariasis in Ghana: entomological inves-₉₆₁ 890 tigation of transmission dynamics and intensity in communities served₉₆₂ 891 by irrigation systems in the Upper East Region of Ghana." Tropical₉₆₃ 892 medicine & international health : TM & IH vol. 6,7 (2001): 511-6. ⁸⁹³ doi:10.1046/j.1365-3156.2001.00737.x
- 894 [5] Basu, Saurav et al. "Detecting and visualizing cell phenotype differences₉₆₆ 895 from microscopy images using transport-based morphometry." Proceed-₉₆₇ 896 ings of the National Academy of Sciences of the United States of America_{nce} ⁸⁹⁷ vol. 111,9 (2014): 3448-53. doi:10.1073/pnas.1319779111
- 898 [6] Bojke, Laura et al. "Characterizing structural uncertainty in decision₉₇₀ 899 analytic models: a review and application of methods." Value in_{971} 900 health: the journal of the International Society for Pharmacoeconomics₉₇₂ 901 and Outcomes Research vol. 12,5 (2009): 739-49. doi:10.1111/j.1524-⁹⁰² 4733.2008.00502.x
- 903 [7] Brady, Molly A et al. "Costs of Transmission Assessment Surveys₉₇₅ 904 to Provide Evidence for the Elimination of Lymphatic Filariasis." ₉₇₆ 905 PLoS Neglected Tropical Diseases vol. 11,2 e0005097. 1 Feb. 2017,₉₇₇ ⁹⁰⁶ doi:10.1371/journal.pntd.0005097.
- 907 [8] Brennan, Alan et al. "Calculating partial expected value of perfect infor-₉₇₉ ⁹⁰⁸ mation via Monte Carlo sampling algorithms." Medical decision making 909 : an international journal of the Society for Medical Decision Making vol. ⁹¹⁰ 27,4 (2007): 448-70. doi:10.1177/0272989X07302555
- 911 [9] Calder, Jeff et al. "Poisson Learning: Graph Based Semi-Supervised 912 Learning At Very Low Label Rates." International Conference on Ma-₉₈₄ ⁹¹³ chine Learning (2020).
- [10] Caroline Moosmüller, Alexander Cloninger, Linear optimal transport embedding: provable Wasserstein classification for certain rigid transformations and perturbations, Information and Inference: A Journal of the IMA, Volume 12, Issue 1, March 2023, Pages 363-389, ⁹¹⁸ https://doi.org/10.1093/imaiai/iaac023
- [11] Cedric, Villani. Topics in Optimal Transportation. American Mathematical Society, 2003.
- [12] Chi, Y-Ling et al. "What next after GDP-based cost-effectiveness thresholds?." Gates open research vol. 4 176. 30 Nov. 2020, ⁹²³ doi:10.12688/gatesopenres.13201.1
- $[13]$ Chan, M S et al. "Epifil: a dynamic model of infection and disease in lymphatic filariasis." The American Journal of tropical medicine and Hygiene ⁹²⁶ vol. 59,4 (1998): 606-14. doi:10.4269/ajtmh.1998.59.606.
- ⁹²⁷ [14] Chu BK, Hooper PJ, Bradley MH, et al. The economic benefits resulting ⁹²⁸ from the first 8 years of the Global Programme to Eliminate Lymphatic ⁹²⁹ Filariasis (2000–2007). PLoS Negl Trop Dis 2010;4:e708.
- ⁹³⁰ [15] Claxton, K., et al. "Probabilistic Sensitivity Analysis for Decision Making ⁹³¹ in Health Care: The Value of Collecting Information." Medical Decision Making, 2005.
	- [16] Davis, E. L., Reimer, L. J., Pellis, L., and Hollingsworth, T. D. (2019). Evaluating the Evidence for Lymphatic Filariasis Elimination. Trends in ⁹³⁵ parasitology, 35(11), 860–869. https://doi.org/10.1016/j.pt.2019.08.003
	- [17] Derua YA, Rumisha SF, Batengana BM, Max DA, Kisinza WN, Mboera ⁹³⁷ LE. Lymphatic filariasis transmission on Mafia Islands, Tanzania: Evidence from xenomonitoring in mosquito vectors. PLoS neglected tropical ⁹³⁹ diseases. 2017;11(10):e0005938 10.1371/journal.pntd.0005938
- [18] Dyson, Louise et al. "Measuring and modelling the effects of systematic ⁹⁴¹ non-adherence to mass drug administration." Epidemics vol. 18 (2017): ⁹⁴² 56-66. doi:10.1016/j.epidem.2017.02.002
- ⁹⁴³ [19] Gambhir, Manoj, and Edwin Michael. "Complex ecological dy-⁹⁴⁴ namics and eradicability of the vector borne macroparasitic dis-⁹⁴⁵ ease, lymphatic filariasis." PloS one vol. 3,8 e2874. 6 Aug. 2008, ⁹⁴⁶ doi:10.1371/journal.pone.0002874
- [20] Griffin, S., Fusco, F., Naidoo, B., Taylor, M., & Walker, S. M. (2020). Does Health Technology Assessment guidance give adequate considera-⁹⁴⁹ tion to decisions about less costly and less effective alternatives? (CHE Research Paper; No. 175). Centre for Health Economics, University of York.
	- [21] Global Burden of Disease Study 2019 (GBD 2019) Disability Weights. ⁹⁵³ http://ghdx.healthdata.org/record/ihme-data/gbd-2019-disabilityweights. Accessed 25 March 2022.
	- [22] Heath A, Manolopoulou I, Baio G. Estimating the expected value of par-⁹⁵⁶ tial perfect information in health economic evaluations using integrated nested Laplace approximation. Stat Med. 2016;35(23):4264-80.
	- [23] Heath, Anna et al. "Estimating the Expected Value of Sample Information across Different Sample Sizes Using Moment Matching and Nonlinear Regression." Medical decision making : an international journal of the Society for Medical Decision Making vol. 39,4 (2019): 346-358. doi:10.1177/0272989X19837983.
- [24] Irvine, Michael A et al. "Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study." The Lancet. ⁹⁶⁵ Infectious diseases vol. 17,4 (2017): 451-458. doi:10.1016/S1473- 3099(16)30467-4
- [25] Irvine, Michael A et al. "Modelling strategies to break transmission of lymphatic filariasis–aggregation, adherence and vector competence ⁹⁶⁹ greatly alter elimination." Parasites & vectors vol. 8 547. 22 Oct. 2015, ⁹⁷⁰ doi:10.1186/s13071-015-1152-3.
- [26] Irvine, Michael A et al. "Understanding the relationship between prevalence of microfilariae and antigenaemia using a model of lymphatic filariasis infection." Transactions of the Royal Society of Tropical Medicine ⁹⁷⁴ and Hygiene vol. 110,2 (2016): 118-24. doi:10.1093/trstmh/trv096.
- [27] James, Ananthu et al. "Predictive Value of Microfilariae-Based Stop-⁹⁷⁶ MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings." Clinical in-⁹⁷⁸ fectious diseases : an official publication of the Infectious Diseases Society of America vol. 78,Supplement 2 (2024): S131-S137. ⁹⁸⁰ doi:10.1093/cid/ciae019
	- [28] King, Christopher L et al. "A Trial of a Triple-Drug Treatment for Lymphatic Filariasis." The New England journal of medicine vol. 379,19 (2018): 1801-1810. doi:10.1056/NEJMoa1706854
	- [29] Kunst, Natalia et al. "Computing the Expected Value of Sample Infor-

- 985 mation Efficiently: Practical Guidance and Recommendations for Fouros6 Model-Based Methods." Value in health : the journal of the Interna- tional Society for Pharmacoeconomics and Outcomes Research vol. 23,6 (2020): 734-742. doi:10.1016/j.jval.2020.02.010
- 989 [30] Koschorke, Mirja et al. "Mental health, stigma, and neglected tropicaloso 990 diseases: A review and systematic mapping of the evidence." Frontiers ino61 Tropical Diseases (2022).
- [31] Kolouri, Soheil et al. "Optimal Mass Transport: Signal processing and 993 machine-learning applications." IEEE signal processing magazine volto64 34,4 (2017): 43-59. doi:10.1109/MSP.2017.2695801.
- [32] Kolouri, Soheil and Gustavo Kunde Rohde. "Transport-based single 996 frame super resolution of very low resolution face images." 2015 IEEE067 997 Conference on Computer Vision and Pattern Recognition (CVPR) (2015)1068 4876-4884.
- 999 [33] Mwakitalu, Mbutolwe E et al. "Urban lymphatic filariasis in the metropo-1070 1000 lis of Dar es Salaam, Tanzania." Parasites & vectors vol. 6 286. 30 Septor1 2013, doi:10.1186/1756-3305-6-286
- [34] Michael E, Singh BK. Heterogeneous dynamics, robustness/fragility trade-offs, and the eradication of the macroparasitic disease, lymphatic filariasis. BMC Med 2016; 14:14.
- [35] Ochalek, Jessica et al. "Estimating health opportunity costs in low- income and middle-income countries: a novel approach and evidence from cross-country data." BMJ Global Health vol. 3,6 e000964. 5 Nov. 2018, doi:10.1136/bmjgh-2018-000964.
- [36] Ozolek, John A et al. "Accurate diagnosis of thyroid follicular lesions from nuclear morphology using supervised learning." Medical image ¹⁰⁸¹ 29. analysis vol. 18,5 (2014): 772-80. doi:10.1016/j.media.2014.04.004
- [37] Park, S. & Thorpe, M. Representing and Learning High Dimensional 1013 Data with the Optimal Transport Map from a Probabilistic Viewpoint. In 2018 IEEE/CVF Conference on Computer Vision and Pattern Recog-nition, 7864–7872, https://doi.org/10.1109/CVPR.2018.00820.
- [38] Pichon-Riviere, Andres et al. "Determining the efficiency path to univer- sal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures." The Lancet. Global
- 1019 health vol. 11,6 (2023): e833-e842. doi:10.1016/S2214-109X(23)00162.1090
1020 [39] Rothery, Claire et al. "Value of Information Analytical Methods: Reportos [39] Rothery, Claire et al. "Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 23,3 (2020): 277-286. doi:10.1016/j.jval.2020.01.004.
- [40] Stone CM, Kastner R, Steinmann P, et al, Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying lev-els of mass drug administration scale-up and geographic coverage.BMJ
- 1028 Global Health 2016;1:e000021
1029 [41] Sawers, Larry, and Eileen Stilly [41] Sawers, Larry, and Eileen Stillwaggon. "Economic Costs and Benefits of Community-Based Lymphedema-Management Programs for Lymphatic Filariasis in India." The American journal of tropical medicine and hy-giene vol. 103,1 (2020): 295-302. doi:10.4269/ajtmh.19-0898.
- [42] Samy AM, Elaagip AH, Kenawy MA, Ayres CF, Peterson AT, Soli- man DE. Climate change influences on the global potential distribution of the mosquito Culex quinquefasciatus, vector of West Nile virus and lymphatic filariasis. PLoS ONE. 2016;11(10):e0163863 10.1371/jour-nal.pone.0163863
- [43] Strong M, Oakley J, Brennan A, Breeze P. Estimating the expected value of sample information using the probabilistic sensitivity analysis sam- ple a fast nonparametric regression-based method. Med Decis Making. 2015;35(5): 570–83.
- [44] Strong M, Oakley JE. When is a model good enough? Deriv- ing the expected value of model improvement via specifying internal model discrepancies.SIAM/ASA Journal on Uncertainty Quantification. 1045 2014;2(1):106-125.
- [45] Stolk WA, Prada JM, Smith ME, et al. Are alternative strategies required to accelerate the global elimination of lymphatic filariasis? Insights from mathematical models. Clin Infect Dis 2018; 66:2606.
- [46] Stolk, Wilma A et al. "Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa." PLoS Neglected Tropical Diseases vol. 16,12 e0010953. 12 Dec. 2022, doi:10.1371/journal.pntd.0010953
- [47] Stolk, Wilma A et al. "Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic fi-lariasis." PLoS Neglected Tropical Diseases vol. 7,1 (2013): e1984.

doi:10.1371/journal. and.0001984.

- [48] Turner, Hugo C et al. "An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations." Frontiers in public health vol. 9 722927. 25 Aug. 2021, doi:10.3389/fpubh.2021.722927
	- [49] Ton, T.G., Mackenzie, C. and Molyneux, D.H. The burden of mental health in lymphatic filariasis. Infect Dis Poverty 4, 34 (2015). https://doi.org/10.1186/s40249-015-0068-7
- [50] Turner, Hugo C et al. "An Updated Economic Assessment of Mox- idectin Treatment Strategies for Onchocerciasis Elimination." Clini- cal infectious diseases : an official publication of the Infectious Diseases Society of America vol. 78,Supplement 2 (2024): S138-S145. doi:10.1093/cid/ciae054.
- [51] Turner, Hugo C et al. "Adjusting for Inflation and Currency Changes Within Health Economic Studies." Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 22,9 (2019): 1026-1032. doi:10.1016/j.jval.2019.03.021
- [52] Vallejo-Torres, Laura et al. "Challenges of calculating cost-effectiveness thresholds." The Lancet. Global health vol. 11,10 (2023): e1508. doi:10.1016/S2214-109X(23)00351-0
	- [53] World Health Organization (WHO). Weekly Epidemiological Record (WER), 13 October 2023, Vol. 98, No. 41, pp. 489 - 502.
- [54] World Health Organization (WHO). Lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration, a manual for national elimination programmes. Geneva, Switzerland: WHO, 2011, page
- [55] W. Wang, D. Slepcev, S. Basu, J. A. Ozolek, and G. K. Rohde, "A linear optimal transportation framework for quantifying and visualizing variations in sets of images," Int. J. Comput. Vision, vol. 101, no. 2, pp. 254–269, 2013.
- [56] Wilson E. A Practical Guide to Value of Information Analysis. PharmacoEconomics 2015; 33(2):105–121.
	- [57] World Health Organization Regional Office for the Western Pacific, Control of Lymphatic Filariasis in China Editorial Board. Control of lymphatic filariasis in China. Manila: World Health Organization Regional Office for the Western Pacific; 2003.
	- [58] Wang, W., Mo, Y., Ozolek, J.A., Rohde, G.K.: Penalized discriminant analysis and its application to image-based morphometry. Pattern Recognition Letters
- [59] Willis, Gabriela A et al. "A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018." PLoS neglected tropical diseases vol. 14,11 e0008854. 30 Nov. 2020, doi:10.1371/journal.pntd.0008854.
- [60] World Health Organization, Baltussen, Rob M. P. M, Adam, Taghreed, Tan-Torres Edejer, Tessa, Hutubessy, Raymond C. W. et al. (2003). Making choices in health : WHO guide to cost-effectiveness analysis. World Health Organization.